New Drugs 2014-2015 Part 2- Pharmacy Technician

  Price  

  Credits  1.5

This product is currently out of stock and unavailable.


Format
In the New Drugs Part 1 issue (April 2015), we focused on 2 products for treatment of hepatitis C, 2 weight loss products, the first-in-class orexin receptor antagonist for insomnia, and a new formulation of inhaled human insulin. Because of the large number of new approvals in 2014 and early 2015, we decided to publish a second New Drugs issue this year. Even so, it was a difficult choice among many more novel agents than we could cover. New Drugs Part 2 includes the first oral peripherallyacting opioid antagonist for opioid-induced constipation; 3 antibacterials for acute skin and skin structure infections; the first-in-class interleukin 17A antagonist for plaque psoriasis; and 6 new cancer drugs. The 3 antibacterials were approved as Qualified Infectious Disease Products (QIDPs)1 – ie, antimicrobials intended to treat serious or life-threatening infections. This designation – created in 2012 by the Generating Antibiotics Incentive Now Act, which is part of the FDA Safety and Innovation Act – provides incentives for the development of new antibiotics, with priority review and the possibility of fast-track status.2 The 6 cancer drugs received accelerated approval, with continued approval contingent upon confirmation of clinical benefit in subsequent studies.3 Table 1 lists the indications, usual doses, and selected interactions for these drugs. Table 2 provides brief reviews of additional new drugs or formulations that are also likely to be of interest to community practitioners. Selected new combinations are described in Table 3 (see Addendum, pages 12-13).

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Tech Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacy Technician : 0428-0000-15-005-H01-T
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.